1016 related articles for article (PubMed ID: 25961827)
1. AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis.
Mi W; Ye Q; Liu S; She QB
Oncotarget; 2015 Jun; 6(16):13962-77. PubMed ID: 25961827
[TBL] [Abstract][Full Text] [Related]
2. The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206.
Wang H; Huang F; Wang J; Wang P; Lv W; Hong L; Li S; Zhou J
Cell Cycle; 2015; 14(2):232-42. PubMed ID: 25607647
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells.
Zeng Q; Qin S; Zhang H; Liu B; Qin J; Wang X; Zhang R; Liu C; Dong X; Zhang S; Huang S; Chen L
J Cell Physiol; 2018 Jan; 233(1):516-529. PubMed ID: 28300280
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylation of PRAS40 on Thr246 by PKB/AKT facilitates efficient phosphorylation of Ser183 by mTORC1.
Nascimento EB; Snel M; Guigas B; van der Zon GC; Kriek J; Maassen JA; Jazet IM; Diamant M; Ouwens DM
Cell Signal; 2010 Jun; 22(6):961-7. PubMed ID: 20138985
[TBL] [Abstract][Full Text] [Related]
5. The mechanism of insulin-stimulated 4E-BP protein binding to mammalian target of rapamycin (mTOR) complex 1 and its contribution to mTOR complex 1 signaling.
Rapley J; Oshiro N; Ortiz-Vega S; Avruch J
J Biol Chem; 2011 Nov; 286(44):38043-38053. PubMed ID: 21914810
[TBL] [Abstract][Full Text] [Related]
6. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma.
Ahmed M; Hussain AR; Bavi P; Ahmed SO; Al Sobhi SS; Al-Dayel F; Uddin S; Al-Kuraya KS
Carcinogenesis; 2014 Jul; 35(7):1564-72. PubMed ID: 24583924
[TBL] [Abstract][Full Text] [Related]
7. Feedback loops blockade potentiates apoptosis induction and antitumor activity of a novel AKT inhibitor DC120 in human liver cancer.
Yang F; Deng R; Qian XJ; Chang SH; Wu XQ; Qin J; Feng GK; Ding K; Zhu XF
Cell Death Dis; 2014 Mar; 5(3):e1114. PubMed ID: 24625973
[TBL] [Abstract][Full Text] [Related]
8. Hydrogen peroxide impairs insulin-stimulated assembly of mTORC1.
Zhang L; Kimball SR; Jefferson LS; Shenberger JS
Free Radic Biol Med; 2009 Jun; 46(11):1500-9. PubMed ID: 19281842
[TBL] [Abstract][Full Text] [Related]
9. Constitutive phosphorylation of the mTORC2/Akt/4E-BP1 pathway in newly derived canine hemangiosarcoma cell lines.
Murai A; Asa SA; Kodama A; Hirata A; Yanai T; Sakai H
BMC Vet Res; 2012 Jul; 8():128. PubMed ID: 22839755
[TBL] [Abstract][Full Text] [Related]
10. The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1.
Oshiro N; Takahashi R; Yoshino K; Tanimura K; Nakashima A; Eguchi S; Miyamoto T; Hara K; Takehana K; Avruch J; Kikkawa U; Yonezawa K
J Biol Chem; 2007 Jul; 282(28):20329-39. PubMed ID: 17517883
[TBL] [Abstract][Full Text] [Related]
11. PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex.
Fonseca BD; Smith EM; Lee VH; MacKintosh C; Proud CG
J Biol Chem; 2007 Aug; 282(34):24514-24. PubMed ID: 17604271
[TBL] [Abstract][Full Text] [Related]
12. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
13. RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells.
Gordon BS; Kazi AA; Coleman CS; Dennis MD; Chau V; Jefferson LS; Kimball SR
Cell Signal; 2014 Mar; 26(3):461-7. PubMed ID: 24316235
[TBL] [Abstract][Full Text] [Related]
14. Icariside II, a natural mTOR inhibitor, disrupts aberrant energy homeostasis via suppressing mTORC1-4E-BP1 axis in sarcoma cells.
Zhang C; Yang L; Geng YD; An FL; Xia YZ; Guo C; Luo JG; Zhang LY; Guo QL; Kong LY
Oncotarget; 2016 May; 7(19):27819-37. PubMed ID: 27056897
[TBL] [Abstract][Full Text] [Related]
15. Both mTORC1 and mTORC2 are involved in the regulation of cell adhesion.
Chen L; Xu B; Liu L; Liu C; Luo Y; Chen X; Barzegar M; Chung J; Huang S
Oncotarget; 2015 Mar; 6(9):7136-50. PubMed ID: 25762619
[TBL] [Abstract][Full Text] [Related]
16. ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer.
Ye Q; Cai W; Zheng Y; Evers BM; She QB
Oncogene; 2014 Apr; 33(14):1828-39. PubMed ID: 23624914
[TBL] [Abstract][Full Text] [Related]
17. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.
Zhou X; Tan M; Stone Hawthorne V; Klos KS; Lan KH; Yang Y; Yang W; Smith TL; Shi D; Yu D
Clin Cancer Res; 2004 Oct; 10(20):6779-88. PubMed ID: 15501954
[TBL] [Abstract][Full Text] [Related]
18. Phosphatidylinositol-3 kinase-dependent translational regulation of Id1 involves the PPM1G phosphatase.
Xu K; Wang L; Feng W; Feng Y; Shu HK
Oncogene; 2016 Nov; 35(44):5807-5816. PubMed ID: 27065332
[TBL] [Abstract][Full Text] [Related]
19. Growth-factor dependent expression of the translationally controlled tumour protein TCTP is regulated through the PI3-K/Akt/mTORC1 signalling pathway.
Bommer UA; Iadevaia V; Chen J; Knoch B; Engel M; Proud CG
Cell Signal; 2015 Aug; 27(8):1557-68. PubMed ID: 25936523
[TBL] [Abstract][Full Text] [Related]
20. PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding.
Wang L; Harris TE; Roth RA; Lawrence JC
J Biol Chem; 2007 Jul; 282(27):20036-44. PubMed ID: 17510057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
